Review



nf2 men luc2  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Jackson Laboratory nf2 men luc2
    The brigatinib + INK128 combination effectively <t>shrank</t> <t>intracranial</t> <t>AG-NF2-Men-Luc2</t> meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.
    Nf2 Men Luc2, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nf2+men+luc2/pmc12835584-81-8-40?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    nf2 men luc2 - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2 -Deficient Meningiomas"

    Article Title: Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2 -Deficient Meningiomas

    Journal: Cancer Research Communications

    doi: 10.1158/2767-9764.CRC-25-0563

    The brigatinib + INK128 combination effectively shrank intracranial AG-NF2-Men-Luc2 meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.
    Figure Legend Snippet: The brigatinib + INK128 combination effectively shrank intracranial AG-NF2-Men-Luc2 meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.

    Techniques Used:



    Similar Products

    nf2 men luc2  (Jackson Laboratory)
    86
    Jackson Laboratory nf2 men luc2
    The brigatinib + INK128 combination effectively <t>shrank</t> <t>intracranial</t> <t>AG-NF2-Men-Luc2</t> meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.
    Nf2 Men Luc2, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nf2+men+luc2/pmc12835584-81-8-40?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    nf2 men luc2 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    The brigatinib + INK128 combination effectively shrank intracranial AG-NF2-Men-Luc2 meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.

    Journal: Cancer Research Communications

    Article Title: Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2 -Deficient Meningiomas

    doi: 10.1158/2767-9764.CRC-25-0563

    Figure Lengend Snippet: The brigatinib + INK128 combination effectively shrank intracranial AG-NF2-Men-Luc2 meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.

    Article Snippet: The clone expressing the highest luciferase activity, designated AG-NF2-Men-Luc2, was tested for its ability to establish xenografts by injecting 5 × 10 5 cells subcutaneously in the flank or stereotactically into the skull base of 8- to 12-week-old NSG mice (The Jackson Laboratory).

    Techniques: